Yann Godet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9104542/publications.pdf

Version: 2024-02-01

18	457	759233 12	839539 18
papers	citations	h-index	g-index

18	18	18	694
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma. Journal of Investigative Dermatology, 2022, 142, 435-444.	0.7	15
2	Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy. Cancers, 2022, 14, 260.	3.7	26
3	Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells. Cancers, 2022, 14, 3168.	3.7	8
4	An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells. Cellular Immunology, 2021, 363, 104314.	3.0	5
5	Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells. Cancer Gene Therapy, 2021, , .	4.6	2
6	CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. International Journal of Cancer, 2019, 145, 3112-3125.	5.1	32
7	Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy. Human Gene Therapy, 2018, 29, 1202-1212.	2.7	8
8	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice. Oncotarget, 2017, 8, 48959-48971.	1.8	5
9	Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4⁺Th1 responses against telomerase in cancer patients. OncoImmunology, 2016, 5, e1137416.	4.6	21
10	Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells. Journal of Immunology, 2016, 197, 1597-1608.	0.8	16
11	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. Cancer Research, 2016, 76, 4100-4112.	0.9	42
12	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Experimental Hematology and Oncology, 2015, 5, 7.	5.0	17
13	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines, 2015, 3, 490-502.	4.4	43
14	CD20 alternative splicing isoform generates immunogenic <scp>CD</scp>4 helper <scp>T</scp> epitopes. International Journal of Cancer, 2015, 137, 116-126.	5.1	29
15	Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 1073-1077.	3.3	20
16	Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. OncoImmunology, 2013, 2, e23430.	4.6	17
17	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. Clinical Cancer Research, 2012, 18, 6284-6295.	7.0	54
18	Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. Clinical Cancer Research, 2012, 18, 2943-2953.	7.0	97